Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
PR90785
AHMEDABAD, India, July 22, 2021 /PRNewswire=KYODO JBN/ --
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing
access to high quality medicines by entering into an exclusive license
agreement
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing
access to high quality medicines by entering into an exclusive license
agreement with Meiji and Dong-A Socio Holdings (a parent company of Dong-A ST)
to commercialize DMB-3115, a proposed biosimilar to ustekinumab, a recombinant
monoclonal antibody for the treatment of autoimmune and inflammatory diseases
such as plaque psoriasis, Crohn's disease and ulcerative colitis.
Under the terms of the agreement, Intas have been granted exclusive license
rights to commercialize DMB-3115 worldwide, excluding Japan, Korea and certain
countries in Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115
and supply the product to Intas and its worldwide affiliates.
This is yet another industry first for Intas, one of the leaders in the
development and commercialization of biosimilar products, who are the first
Indian company to launch a biosimilar product in the EU.
"We are truly excited by this partnership, which brings together the
development expertise of Meiji and Dong-A ST with the extensive commercial
reach of Intas," said Vice Chairman, Mr. Binish Chudgar. "This agreement
underlines our vision and commitment to increase access to life-changing
medicines that can make a real difference to patient lives across the world,"
said Chrys Kokino, President of Accord BioPharma, Inc., the US specialty
subsidiary of Intas.
About Dong-A ST
Dong-A is one of the leading pharmaceuticals in Korea. Dong-A has solidified
its leading market position on the strength of in-house developed products such
as Suganon tab. Evogliptin, the DPP-4 inhibitor for type 2 diabetes mellitus,
Zydena tab. Udenafil, the fourth PDE5 inhibitor in the world for erectile
dysfunction, Stillen tab. Eupatilin for herbal treatment of gastritis and
Motilitone tab. Corydaline for functional dyspepsia. Furthermore, Dong-A offers
branded generic drugs (anti-cancer, anti-TB, etc.), bio-pharmaceutical, IMD,
APIs and OTC products ensuring full compliance with international quality
standard. Currently Dong-A exports its products to more than 50 countries to
leading pharmaceutical companies in Europe, Latin America and Asia.
For more information, please visit http://en.donga-st.com.
About Meiji
Meiji is a leading pharmaceutical company in Japan in the therapeutic areas of
infectious diseases and central nervous system disorders. Since entering pharma
industry with launch of penicillin in 1946, Meiji has been accumulating
proprietary technologies on R&D and manufacture of small molecules as well as
biotherapeutics and is providing high-quality pharmaceutical products to
customers in Japan and overseas. Meiji continues to accommodate customer's
diverse medical requirements as a "Specialty and Generic Pharmaceuticals
Company".
For more information, please visit
https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/
About Intas
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical
company based in Ahmedabad, India, having end-to-end capabilities of
formulation development, manufacturing and marketing along with backward
integration of APIs. Intas has more than 16,000 employees, sells products in
more than 85 countries and has 14 manufacturing sites worldwide. The Intas
group's revenues amounted to USD 2.1 bn in FY 2020 and the compounded annual
growth rate of Intas' revenues has exceeded 25% in the past 10 years.
For more information, please visit www.intaspharma.com
Source: Intas Pharmaceuticals Ltd
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。